We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Efficacy and safety of beclomethasone dipropionate breath-actuated or metered-dose inhaler in pediatric patients with asthma.
- Authors
Vandewalker, Mark; Hickey, Lisa; Small, Calvin J.
- Abstract
Background: Breath-actuated inhalers (BAI) eliminate the need for hand-breath coordination and, therefore, simplify the delivery of inhaled medication. Objective: To evaluate the efficacy and safety of beclomethasone dipropionate BAI and metered-dose inhaler (MDI) versus placebo in pediatric patients ages 4-11 years with persistent asthma. Methods: In this double-blind, double-dummy, phase III study, 628 children with persistent asthma were randomly assigned (1:1:1:1:1) to twice-daily beclomethasone dipropionate (BAI 80 µg/day, BAI 160 µg/day, MDI80 µg/day, or MDI 160 µg/day) or to placebo. Efficacy over 12 weeks was assessed by spirometry, peak expiratory flow (PEF) measurements and other clinical end points. The primary efficacy end point was the baseline-adjusted trough morning percent predicted forced expiratory volume in 1 second (PPFEV1) area under the effect curve from 0 to 12 weeks (AUEC[0-12 weeks]). Results: PPFEV1 AUEC(0-12 weeks) showed numerical improvements from baseline in the BAI 80 µg/day and BAI 160 µg/day groups and MDI 80 µg/day and MDI 160 µg/day groups; however, these improvements were not significant versus placebo for any group after hierarchical testing was applied. Consistent improvements were noted in the active treatment groups versus placebo for the weekly average trough morning and evening PEFs, and with BAI 80 xg/day versus placebo for rescue albuterol/salbutamol use and the total daily asthma symptom score. Most patients indicated that the BAI device was easy or very easy to use. Adverse events were comparable across the groups; the incidence of oral candidiasis ranged from 0.8 to 3.2%. Conclusions: Although the primary efficacy end point was not demonstrated, consistent improvements in PEF and other clinical end points were observed with beclomethasone dipropionate BAI, particularly at the 80 µg/day dose. These clinical benefits, combined with the need for better symptom control in children with asthma, supported the development of beclomethasone dipropionate BAI.
- Subjects
DRUG efficacy; MEDICATION safety; BECLOMETHASONE dipropionate; ASTHMA in children; ASTHMA treatment; METERED-dose inhalers
- Publication
Allergy & Asthma Proceedings, 2017, Vol 38, Issue 5, p354
- ISSN
1088-5412
- Publication type
Article
- DOI
10.2500/aap.2017.38.4078